Opioid-Buprenorphine Combination Reduces Respiratory Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid therapies for pain management often result in adverse pharmacodynamic responses such as respiratory depression, addiction, and drug abuse, posing safety concerns and public health risks.
Innovation Solution
The use of specific combinations of opioid agonists (such as oxycodone, fentanyl, and hydromorphone) with buprenorphine, administered in certain ratios and overlapping administration periods, to reduce adverse responses and improve safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stand-alone opioid agonist treatments (oxycodone, fentanyl, hydromorphone) are used for pain management, then effective pain relief is achieved, but respiratory depression and adverse pharmacodynamic responses occur
Solution Approach 1:
The patent combines opioid agonists (oxycodone, fentanyl, or hydromorphone) with buprenorphine in specific ratios to create a composite treatment formulation. This merging of two substances with different pharmacological properties allows the beneficial pain-relief effects of the opioid agonist to be tempered by the ceiling effect of buprenorphine, thereby reducing respiratory depression while maintaining analgesia.
Solution Approach 2:
The patent specifies precise parameter ranges for the combination therapy, including the ratio of opioid agonist to buprenorphine (e.g., 1:0.01 to 1:10), administration timing (within 6 hours of each other), and dosing frequencies. By controlling these parameters, the treatment achieves effective pain relief while minimizing respiratory depression through the ceiling effect of buprenorphine.
2Reliability
If stand-alone opioid agonist treatments are used for pain management, then effective pain relief is achieved, but addiction and drug abuse potential increase
Solution Approach 1:
The patent merges full opioid agonists with buprenorphine, a partial agonist with a ceiling effect. This combination dilutes the abuse potential of the full agonist while maintaining sufficient analgesic activity, as buprenorphine caps the maximal opioid effect at sub-euphoric levels, thereby reducing the incentive for misuse.
Solution Approach 2:
Buprenorphine acts as an intermediary substance that modulates the effects of the full opioid agonist. By binding to opioid receptors with higher affinity and producing a ceiling effect, buprenorphine intermediates the pharmacological action, preventing the full agonist from producing euphoria or excessive respiratory depression, thus reducing abuse potential.
3Reliability
If higher doses of opioid agonists are administered to improve pain relief, then analgesia effectiveness increases, but adverse pharmacodynamic responses worsen
Solution Approach 1:
The patent changes the dosing parameters by introducing buprenorphine at specific ratios (e.g., 1:0.01 to 1:10) relative to the opioid agonist. This parameter adjustment creates a ceiling effect that caps the maximal respiratory depression and adverse effects, allowing clinicians to administer higher analgesic doses without proportionally increasing harm.
Solution Approach 2:
Buprenorphine is administered beforehand or concurrently with the opioid agonist to cushion against excessive adverse effects. The ceiling effect of buprenorphine acts as a pre-established safety mechanism that prevents respiratory depression and other adverse pharmacodynamic responses from becoming life-threatening, even when high doses of the full agonist are used.
Data Source
AI summary
The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g/mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g/mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.